Patients with Huntington’s disease, a fatal genetic illness that causes the breakdown of nerve cells in the brain, have up to 80 percent less cancer than the general population.
Northwestern Medicine scientists have discovered why Huntington’s is so toxic to cancer cells and harnessed it for a novel approach to treat cancer, a new study reports.
Huntington’s is caused by an over abundance of a certain type of repeating RNA sequences in one gene, huntingtin, present in every cell. The defect that causes the disease also is highly toxic to tumor cells. These repeating sequences — in the form of so-called small interfering RNAs — attack genes in the cell that are critical for survival. Nerve cells in the brain are vulnerable to this form of cell death, however, cancer cells appear to be much more susceptible.
“This molecule is a super assassin against all tumor cells,” said senior author Marcus Peter, the Tom D. Spies Professor of Cancer Metabolism at Northwestern University Feinberg School of Medicine. “We’ve never seen anything this powerful.”
Huntington’s disease deteriorates a person’s physical and mental abilities during their prime working years and has no cure.
The study will be published Feb. 12 in the journal EMBO Reports.
To test the super assassin molecule in a treatment situation, Peter collaborated with Dr. Shad Thaxton, associate professor of urology at Feinberg, to deliver the molecule in nanoparticles to mice with human ovarian cancer. The treatment significantly reduced the tumor growth with no toxicity to the mice, Peter said. Importantly, the tumors did not develop resistance to this form of cancer treatment.
Peter and Thaxton are now refining the delivery method to increase its efficacy in reaching the tumor. The other challenge for the scientists is figuring out how to stabilize the nanoparticles, so they can be stored.
First and co-corresponding author Andrea Murmann, research assistant professor in medicine at Feinberg, also used the molecule to treat human and mouse ovarian, breast, prostate, liver, brain, lung, skin and colon cancer cell lines. The molecule killed all cancer cells in both species.
The Huntington’s cancer weapon was discovered by Murmann, who had worked with Peter on earlier research that identified an ancient kill-switch present in all cells that destroys cancer.
“I thought maybe there is a situation where this kill switch is overactive in certain people, and where it could cause loss of tissues,” Murmann said. “These patients would not only have a disease with an RNA component, but they also had to have less cancer.”
She started searching for diseases that have a lower rate of cancer and had a suspected contribution of RNA to disease pathology. Huntington’s was the most prominent.
When she looked at the repeating sequences in huntingtin, the gene that causes the disease, she saw a similar composition to the earlier kill switch Peter had found. Both were rich in the C and G nucleotides (molecules that form the building blocks of DNA and RNA).
“Toxicity goes together with C and G richness,” Murmann said. “Those similarities triggered our curiosity.”
In the case of people who have Huntington’s, the gene huntingtin has too many repeating sequences of the triplet sequence CAG. The longer the repeating sequence, the earlier they will develop the disease.
“We believe a short-term treatment cancer therapy for a few weeks might be possible, where we could treat a patient to kill the cancer cells without causing the neurological issues that Huntington’s patients suffer from,” Peter said.
Peter also is co-leader of the Translational Research in Solid Tumors Program at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University.
Huntington’s patients have a lifetime exposure to these toxic RNA sequences, but generally don’t develop symptoms of the disease until age 40, he noted.
Every child of a parent with Huntington’s has 50/50 chance of carrying the faulty gene. Today, there are approximately 30,000 symptomatic Americans and more than 200,000 at-risk of inheriting the disease.
Learn more: Huntington’s disease provides new cancer weapon
The Latest on: Cancer therapy
via Google News
The Latest on: Cancer therapy
- Multimodal therapy may hold key to treating aggressive childhood canceron May 16, 2021 at 2:01 pm
Research led by scientists at Children's Cancer Institute and published this week in the international journal, Clinical Cancer Research, has found a combination of therapies that appears to be highly ...
- A Call for Nuance in Cardioprotection With Early Breast Cancer Therapyon May 16, 2021 at 1:40 pm
For low-risk breast cancer patients getting potentially cardiotoxic treatment, candesartan's (Atacand) short-term protection of cardiac function faded longer term in the PRADA trial. Left ventricular ...
- Med City start-up works to create a better canine cancer treatmenton May 16, 2021 at 12:35 pm
Life Engine Animal Health or LEAH Labs, led by CEO and co-founder Wes Wierson, uses non-viral CAR T cell cancer therapy to try to create a better treatment for B cell lymphoma cancer in dogs. That ...
- Young mum, 33, diagnosed with breast cancer eight days before giving birth to her first child was told to 'massage a lump' before she learned the shocking truthon May 15, 2021 at 11:43 pm
A first-time mum who was diagnosed with breast cancer eight days before giving birth has warned 'no one is immune' and to be thorough with health checks.
- Cancer patients often charged exorbitant fees for parkingon May 15, 2021 at 3:00 am
Parking at some prestigious cancer centers can run into hundreds of dollars. The overlooked cost is finally drawing scrutiny from hospital administrators.
- Hyperactivation of HER2-SHCBP1-PLK1 axis promotes tumor cell mitosis and impairs trastuzumab sensitivity to gastric canceron May 14, 2021 at 3:54 pm
Resistance to Trastuzumab in HER2 gastric cancer patients remains a clinical challenge. In this study, the authors demonstrate that HER2 promotes tumorigenesis in gastric cancer by regulating mitotic ...
- The loss of SHMT2 mediates 5-fluorouracil chemoresistance in colorectal cancer by upregulating autophagyon May 14, 2021 at 2:51 pm
Fluorouracil (5-FU)-based chemotherapy is the first-line treatment for colorectal cancer (CRC) but is hampered by chemoresistance. Despite its impact on patient survival, the mechanism underlying ...
- Dr. Horwitz on the Evolution of Radiation Therapy in Prostate Canceron May 14, 2021 at 2:34 pm
Horwitz, MD, FABS, FASTRO, discusses the evolution of radiation therapy in prostate cancer. Eric M. Horwitz, MD, FABS, FASTRO, chair of radiation oncology, professor, and Gerald E. Hanks Endowed Chair ...
- AHN Cancer Institute Becomes One of Nation's First to Use Breakthrough Technology to Advance Radiation Therapyon May 14, 2021 at 12:00 pm
Elekta Unity MR-Linac System Combines MRI Guidance with Radiation Dosing to Minimize Harm to Healthy Tissue When Treating Malignant Tumors ...
- Hollyoaks' Martine chooses not to have cancer treatmenton May 14, 2021 at 11:30 am
Martine Deveraux has decided she won't go through with any treatment options for her breast cancer diagnosis in Hollyoaks. She received the life-changing news earlier this week that the abnormal lump ...
via Bing News